AVITA Medical's RECELL GO mini Receives FDA Approval for Smaller Wound Treatment
Key Insights
AVITA Medical's RECELL GO mini (search) has been approved by the FDA for treating smaller full-thickness skin defects, up to 480 square centimeters.
The RECELL GO mini (search) utilizes the same processing device as the standard RECELL GO but with a modified cartridge optimized for smaller skin samples, reducing waste.
This approval expands the accessibility of RECELL technology to a broader range of patients, particularly in trauma and burn centers where smaller wounds (search) are common.
AVITA Medical Inc (ASX: AVH) has secured FDA approval for its premarket approval (PMA) supplement for RECELL GO mini (search), a line extension of the existing RECELL GO system designed to treat smaller wounds (search). The announcement led to a surge in the company's shares on the ASX.
RECELL GO mini (search) is tailored for full-thickness skin defects up to 480 square centimeters, addressing a critical need for treating smaller wounds (search), while the standard RECELL GO cartridge treats areas up to 1,920 square centimeters. This new offering is designed to minimize resource use and waste by using a modified cartridge optimized for smaller skin samples, while still utilizing the same multi-use processing device as the standard RECELL GO.
Addressing Unmet Needs in Wound Care
The RECELL GO mini (search) aims to provide an entry point for clinicians who may not have previously used the RECELL GO platform for smaller wounds (search), thereby broadening accessibility and use in trauma and burn centers. The design is intended to meet the needs of a high volume of smaller wounds, which are frequently encountered in clinical practice.
Management Perspective
Jim Corbett, CEO of AVITA Medical, expressed enthusiasm about the FDA approval, stating, "The FDA approval of RECELL GO mini (search) strengthens our ability to provide clinicians with fit-for-purpose solutions that meet the diverse needs of patients with full-thickness wounds (search). By introducing a treatment option specifically for smaller wounds, we are expanding the accessibility of RECELL to a wider range of patients. We believe this addition will drive greater adoption across trauma centers, where smaller wounds are common, and support our broader growth strategy."
Commercialization Strategy
AVITA Medical plans to roll out RECELL GO mini (search) in the first quarter of 2025, focusing on trauma and burn centers that frequently treat smaller wounds (search). The company anticipates that RECELL GO mini will serve as a growth driver within the broader RECELL GO platform, furthering the company's strategy to expand its impact on patient care.